厚生省医薬安全局．非臨床薬物動態試験ガイドライン．平成 10（1998）年 6 月 26日医薬審第 496 号．
厚生労働省医薬・生活衛生局．医薬品開発と適正な情報提供のための薬物相互作用ガイドライン．平成 30（2018）年 7 月 23 日薬生薬審発 0723 第 4 号．
田辺三菱製薬株式会社．セレジスト錠 5 mg 医薬品インタビューフォーム 改訂第 5 版．2013 年 9 月．
Akamine Y, Yasui-Furukori N, Uno T. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism. Curr Drug Metab. 2019; 20: 124-129.
Balimane PV, Marino A, Chong S. P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?. AAPS J. 2008; 10: 577-586.
Bassiri RM, Utiger RD. Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans. J Clin Invest. 1973; 52: 1616-1619.
Bohnert T, Patel A, Templeton I, et al. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective. Drug Metab Dispos. 2016; 44: 1399-1423.
Bruderer S, Hopfgartner G, Seiberling M. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42: 901–10.
Daimon CM, Chirdon P, Maudsley S, Martin B. The role of thyrotropin releasing hormone in aging and neurodegenerative diseases. Am J Alzheimers Dis (Columbia). 2013; 1. doi: 10.7726/ajad.2013.1003.
Di L. The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol. 2014; 10: 379-93.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000; 38:41-57.
European medicines agency (EMA). Guideline on the investigation of drug interactions, June 2012 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf. [last accessed 28 January 2020].
Griffiths EC. Clinical applications of thyrotrophin-releasing hormone. Clinical Sci 1987; 73: 449-57.
Griffiths EC. Peptidase inactivation of hypothalamic releasing hormones. Horm Res. 1976;7: 179-191.
Guillemin, R. Peptides in the brain: the new endocrinology of the neuron. Science. 1978; 202: 390–402.
Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther. 1981; 29: 408–13.
Horita A, Carino MA, Lai H. Pharmacology of thyrotropin-releasing hormone. Ann Rev Pharmacol Toxicol. 1986; 26: 311-32.
Horita A. An update on the CNS actions of TRH and its analogs. Life Sci 1998; 62: 1443-8.
Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 2009; 49: 513–33.
Ijiro T, Nakamura K, Ogata M, et al. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system. Eur J Pharmacol. 2015; 761: 413–22.
Ijiro T, Yaguchi A, Yokoyama A, Abe Y, Kiguchi S. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya. Eur J Pharmacol. 2020; 882: 173271.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2), 2009.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Final Concept Paper M12: Drug Interaction Studies, 2019.
Isin EM, Elmore CS, Nilsson GN, et al. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol 2012; 25: 532–42.
Ito S, Ando H, Ose A, et al. Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties. J Pharm Sci. 2013; 102: 3294–3301.
Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit. 1997; 19: 609-613.
Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos. 1994; 22: 849-857.
Kainuma T, Morikawa S, Tagawa K et al. Clinical phase I study of TA-0910 –Oral single dose study–. Rinsyoiyaku. 1997a; 13: 2501-2515.
Kainuma T, Morikawa S, Tagawa K et al. Clinical phase I study of TA-0910 –Oral repeated dose study–. Rinsyoiyaku. 1997b; 13 (10): 2517-2532.
Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004; 44: 919-927.
Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther. 1997; 62: 510-517.
Khomane KS, Meena CL, Jain R, Bansal AK. Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat. 2011; 21: 1673–1691.
Kinoshita K. Yamamura M. Suzuki M. Matsuoka Y. Taltirelin hydrate (TA-0910): an orally active thyrotropin-releasing hormone mimetic agent with multiple actions. CNS Drug Rev. 1998; 4: 25–41.
Kobayashi K, Abe Y, Harada H, et al. Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. Xenobiotica. 2019a; 49:106-119.
Kobayashi K, Abe Y, Kawai A, et al. Human mass balance, pharmacokinetics and metabolism of rovatirelin and identification of its metabolic enzymes in vitro. Xenobiotica. 2019b; 49: 1434-1446.
Kobayashi N, Sato N, Fujimura Y, et al. Correction to discovery of the Orally Effective Thyrotropin-Releasing Hormone Mimetic: 1-{N-[(4S,5S)-(5-Methyl-2-oxooxazolidine4-yl)carbonyl]-3-(thiazol-4-yl)-l-alanyl}-(2R)-2-methylpyrrolidine Trihydrate (Rovatirelin Hydrate). ACS Omega. 2019; 4: 6977-6978.
Kobayashi N, Sato N, Fujimura Y, et al. Discovery of the Orally Effective ThyrotropinReleasing Hormone Mimetic: 1-{N-[(4S,5S)-(5-Methyl-2-oxooxazolidine-4- yl)carbonyl]-3-(thiazol-4-yl)-l-alanyl}-(2R)-2-methylpyrrolidine Trihydrate (Rovatirelin Hydrate). ACS Omega. 2018; 3: 13647-13666.
Kodama H, Furuuchi S, Takahashi M, et al. Disposition of taltirelin (1): absorption, distribution, metabolism and excretion in rats and dogs. Yakubutsudoutai. 1997; 12: 460-74.
Lindell M, Karlsson MO, Lennernäs H, Påhlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest. 2003; 33: 493-499.
Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008; 4: 697- 720.
Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75: 13-33.
Matsunaga Y, Morimoto KH, Terauchi Y, et al. Disposition of posatirelin. (3). metabolites in rats. Yakubutsudoutai. 1996; 11: 273-9.
Morley JE. Extrahypothalamic thyrotropin releasing hormone (TRH) - its distribution and its functions. Life Sci. 1979; 25: 1539-1550.
Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible tointeraction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998; 63: 332-341.
Nijenhuis CM, Schellens JH, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metab Rev. 2016; 48: 266-80.
Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. J Neurol Neurosurg Psychiatry. 2020; 91: 254-262.
Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol. 1978; 235: H299-307.
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 55: 481-485.
O’Leary R, O’Connor B. Thyrotropin-releasing hormone. J Neurochem 1995; 65: 953-63.
Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 2009; 30: 185-203.
Penner N, Xu L, Parakash C. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?. Chem Res Toxicol. 2012; 25:513-31.
Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007; 39:17-43.
Schally AV. Aspects of hypothalamic regulation of the pituitary gland. Science. 1978; 202: 18-28.
Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006; 62: 372-376.
Shimizu Y, Yamano H, Kiyono Y, Ijiro T. Administration regimen for therapeutic agents for ataxia in spinocerebellar degeneration. United States Patent Application Publication. Publication number: US 2018/0147189 A1. Publicatiion Date: May 31, 2018.
Sidhu RS, Blair AH. Human liver aldehyde dehydrogenase. Esterase activity. J Biol Chem. 1975; 250: 7894-8.
Sobue I, Takayanagi T, Nakanishi T, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J. Neurol. Sci. 1983; 61: 235-248.
Sugimoto T, Hayashi T, Okita A, Morino A. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 3rd communication: identification of metabolites in rat urine. Arzneimittelforschung. 1996; 46: 127-33.
Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Itraconazole, a Pglycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol. 2011; 51: 359-67.
Templeton IE, Thummel KE, Kharasch ED, et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther. 2008; 83: 77-85.
U.S. FDA. In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, January 2020. https://www.fda.gov/media/134582/download [last accessed 28 January 2020].
U.S. Food and Drug Administration (FDA). FDA safety testing of drug metabolites guidance for industry, February 2008.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000; 38: 111-180.
Vermeer LM, Isringhausen CD, Ogilvie BW, Buckley DB. Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. Drug Metab Dispos. 2016; 44: 453-459.
Walker D, Brady J, Dalvie D, et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol. 2009; 22: 1653-62.
Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002; 46: 160-165.
Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005; 4: 825-833.
Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDPglucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab and Dispos. 2004; 32: 1201-1208.
Wolfer GK, Rippon WB. Protocols for use of ultrafiltration in determination of free ligand concentration and of complexity of ligand/protein interactions. Clin Chem. 1987; 33: 115-17.
Yamada M, Monden T, Konaka S, Mori M. Assignment of human thyrotropin-releasing hormone (TRH) receptor gene to chromosome 8. Somat. Cell Mol. Genet. 1993; 19: 577-580.
Yokohama S, Yamashita K, Toguchi H, Takeuchi J, Kitamori N. Absorption of thyrotropinreleasing hormone after oral administration of TRH tartrate monohydrate in the rat, dog and human. J Pharmacobiodyn. 1984; 7: 101-11.
Yoshida A, Rzhetsky A, Hsu LC, Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem. 1998; 251: 549-57.
Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 2003; 43: 211-227.
論文の公開元へ
